Results 201 to 210 of about 28,506 (225)

Giant sporadic renal angiomyolipoma as a cause of a massive abdominopelvic mass: A case report. [PDF]

Medicine (Baltimore)
Yan L, Li X, Yuan T, Wang Y.
europepmc   +1 more source

Metabolic changes in mTOR pathway-associated cortical malformation. [PDF]

Front Neurosci
Biswas A, Iffland PH.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A Role of the Mammalian Target of Rapamycin (mTOR) in Glutamate-Induced Down-regulation of Tuberous Sclerosis Complex Proteins 2 (TSC2)

Journal of Molecular Neuroscience, 2012
Mammalian target of rapamycin (mTOR) signaling plays a critical role in the regulation of activity-dependent protein synthesis in neurons. It is well established that the GTPase-activating protein tuberous sclerosis complex proteins (2TSC2) is an upstream inhibitor of mTOR.
Wenjuan, Ru, Yanxi, Peng, Ling, Zhong, Shao-Jun, Tang   +3 more
openaire   +2 more sources

The serine protease HtrA1 specifically interacts and degrades the Tuberous Sclerosis Complex 2 protein (TSC2).

2010
Hamartin and tuberin are products of the tumor suppressor genes TSC1 and TSC2, respectively. Mutations affecting either gene result in the tuberous sclerosis syndrome, a neurologic genetic disorder characterized by the formation of multiple benign tumors or hamartomas. In this study, we report the identification of TSC2, but not TSC1, as a substrate of
Campioni M, Severino A, Manente L, Tuduce IL, Toldo S, Caraglia M, Crispi S, Ehrmann M, De Falco M, de Luca A, He X, Maguire J, Shridhar V, Baldi A   +13 more
openaire   +2 more sources

Faculty Opinions recommendation of Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins. A molecular link of two tumor suppressor pathways.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2004
openaire   +1 more source

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Lancet, The, 2013
David N Franz, Paolo Curatolo, Petrus J De Vries   +2 more
exaly  

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Lancet, The, 2013
John J Bissler, Elzbieta Radzikowska, Norio Nonomura   +2 more
exaly  

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Lancet, The, 2016
Jacqueline A French, Paolo Curatolo, Petrus J De Vries   +2 more
exaly  

Tuberous sclerosis

Lancet, The, 2008
Paolo Curatolo, Sergiusz Jozwiak
exaly  

The Tuberous Sclerosis Complex

New England Journal of Medicine, 2006
Peter B Crino, Katherine L Nathanson
exaly